Proviron dosage for men: what the label and trials give

What the label gives for tablets and doses
ItemUK label (Bayer plc)
Strength25 mg of mesterolone per tablet1
Supply3 blister packs of 10 tablets in an outer pack1
Initial dose, adults3 or 4 tablets daily, for several months1
Maintenance, adults2-3 tablets (50-75 mg) daily1
IndicationAndrogen deficiency or male infertility when associated with primary or secondary male hypogonadism1

For androgen deficiency or male infertility associated with primary or secondary male hypogonadism, the UK Pro-viron label gives adults 3 or 4 tablets daily for several months, then 2-3 tablets (50-75mg) daily.1

What the label gives for tablets and doses

The table is set at the top of the page

At 25 mg a tablet, 2 tablets are 50 mg and 3 tablets are 75 mg.1 The label describes Pro-viron as an orally active androgen, and the NHS dm+d lists the licensed route as oral.12 The label gives no times of day and no instruction about food.1 The initial phase lasts several months, and the label gives no fixed number of weeks or cycle length.1

What trials of mesterolone used

In the trials below, mesterolone doses ran from 50 mg/day by mouth (Dugeroglu 2014, 34 patients, no control arm) to 300-450 mg daily (Itil 1984, 52 men, against placebo); the UK label gives a maintenance dose of 2-3 tablets (50-75mg) daily.341

TrialDose and schedulePeopleLength
Gerris 19915150 mg/d, or placebo (double-blind)52 men with idiopathic oligoasthenospermia and/or teratozoospermia12 months
WHO Task Force 1989675 mg or 150 mg daily, or placebo (double-blind)248 infertile couples6 months
Varma 19887100-150 mg/day, no control groupTwo hundred fifty subfertile men with idiopathic oligospermia12 months
Wang 19838100 mg/day, randomized against placebo, clomiphene citrate, pentoxifylline and testosterone enanthate armsForty-six subfertile men with idiopathic oligospermia6 months
Aafjes 1983975 mg/day, double-blind crossover with placeboFifty-nine carefully selected oligozoospermic men6 months before crossover
Dugeroglu 2014350 mg/day by mouth, cross-sectional, no control arm34 patients with symptoms of aging male syndrome and/or low testosteroneTwo months
Itil 19844300-450 mg daily, or placebo (double-blind)52 male depressed outpatients aged 26-53 years6 weeks

In hypogonadal men, Schubert 2003 (53 men, results after 6 months of therapy) and Jockenhövel 1999 (55 men, 12 of them on mesterolone, taken from days 0 to 189) each had a mesterolone arm of 100 mg daily by mouth, and Jockenhövel 1997 (55 men) had one of 100 mg/d, beside testosterone undecanoate, testosterone enanthate and testosterone implant arms.101112 The published summaries of Hargreave 1984 (368 men), Bhathena 1987 (Forty men), Jackaman 1977 (Forty men) and Luisi 1980 (14 patients on mesterolone) give no mesterolone dose; their full texts were not checked for this guide.13141516

Proviron with TRT or Primobolan

A search of PubMed and ClinicalTrials.gov for this guide found no label or human trial of mesterolone given alongside testosterone or Primobolan (methenolone). The hypogonadism trials above gave mesterolone in its own arm, apart from the testosterone arms. In Jockenhövel 1997 and Jockenhövel 1999, previous testosterone or androgen treatment was suspended for at least 3 months before the study began.1112 Product information wording set by the EU CMDh says mesterolone has been subject to abuse, typically in combination with other anabolic androgenic steroids, and that the abuse of mesterolone and other anabolic androgenic steroids carries serious health risks, including cardiovascular events with fatal outcome in some cases, hepatic and/or psychiatric events, and dependence.17 For cycles in general, see the cycles guide.

How Proviron tablets are stored

The UK label gives a shelf life of 5 years and lists special precautions for storage as none.1 The UK label gives no temperature or humidity condition.1 Bayer's SmPC and patient leaflet texts could not be retrieved for this guide.

Frequently asked questions

Is there a US label or registered trial for mesterolone?

Searches of DailyMed and ClinicalTrials.gov for "mesterolone" and "proviron" found no US label and no registered trial. The NHS dm+d lists a Pro-Viron pack of 50 tablets as discontinued.2

What does the UK label list as contraindications for Proviron?

The UK label lists prostatic carcinoma, previous or existing liver tumours, and hypersensitivity to the active substances or to any of the excipients as contraindications.1 It says Pro-viron is not recommended in children, and that androgens are not suitable for enhancing muscular development in healthy individuals or for increasing physical ability.1

References

  1. MHRA / Bayer plc. Microsoft Word - 285752434769441667_spc-doc.doc. mhraproducts4853.blob.core.windows.net
  2. NHSBSA dm+d. Actual Medicinal Product (AMP) - Pro-Viron 25mg tablets - dm+d browser. dmd-browser.nhsbsa.nhs.uk
  3. PubMed. Mesterolone treatment of aging male syndrome improves lower urinary tract symptoms. 2014. pubmed.ncbi.nlm.nih.gov
  4. PubMed. The effects of mesterolone, a male sex hormone in depressed patients (a double blind controlled study). 1984. pubmed.ncbi.nlm.nih.gov
  5. PubMed. Placebo-controlled trial of high-dose Mesterolone treatment of idiopathic male infertility. 1991. pubmed.ncbi.nlm.nih.gov
  6. PubMed. Mesterolone and idiopathic male infertility: a double-blind study. World Health Organization Task Force on the Diagnosis and Treatment of Infertility. 1989. pubmed.ncbi.nlm.nih.gov
  7. PubMed. The effect of mesterolone on sperm count, on serum follicle stimulating hormone, luteinizing hormone, plasma testosterone and outcome in idiopathic oligospermic men. 1988. pubmed.ncbi.nlm.nih.gov
  8. PubMed. Comparison of the effectiveness of placebo, clomiphene citrate, mesterolone, pentoxifylline, and testosterone rebound therapy for the treatment of idiopathic oligospermia. 1983. pubmed.ncbi.nlm.nih.gov
  9. PubMed. Double-blind cross over treatment with mesterolone and placebo of subfertile oligozoospermic men value of testicular biopsy. 1983. pubmed.ncbi.nlm.nih.gov
  10. PubMed. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. 2003. pubmed.ncbi.nlm.nih.gov
  11. PubMed. Effects of various modes of androgen substitution therapy on erythropoiesis. 1997. pubmed.ncbi.nlm.nih.gov
  12. PubMed. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. 1999. pubmed.ncbi.nlm.nih.gov
  13. PubMed. Randomised trial of mesterolone versus vitamin C for male infertility. Scottish Infertility Group. 1984. pubmed.ncbi.nlm.nih.gov
  14. PubMed. The effects of mesterolone on sperm count in idiopathic oligospermia. 1987. pubmed.ncbi.nlm.nih.gov
  15. PubMed. The hormone response to a synthetic androgen (mesterolone) in oligospermia. 1977. pubmed.ncbi.nlm.nih.gov
  16. PubMed. Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. 1980. pubmed.ncbi.nlm.nih.gov
  17. EMA. Mesterolone: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00010551/202201. ema.europa.eu